1,100 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by AM Squared Ltd

AM Squared Ltd bought a new position in Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,100 shares of the medical research company’s stock, valued at approximately $73,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. GoalVest Advisory LLC lifted its holdings in shares of Edwards Lifesciences by 31.2% during the third quarter. GoalVest Advisory LLC now owns 846 shares of the medical research company’s stock worth $56,000 after buying an additional 201 shares during the last quarter. Maxwell Wealth Strategies Inc. lifted its holdings in shares of Edwards Lifesciences by 27.4% during the third quarter. Maxwell Wealth Strategies Inc. now owns 26,708 shares of the medical research company’s stock worth $1,781,000 after buying an additional 5,742 shares during the last quarter. Empowered Funds LLC lifted its holdings in shares of Edwards Lifesciences by 10.7% during the third quarter. Empowered Funds LLC now owns 24,032 shares of the medical research company’s stock worth $1,586,000 after buying an additional 2,324 shares during the last quarter. Empirical Finance LLC lifted its holdings in shares of Edwards Lifesciences by 2.2% during the third quarter. Empirical Finance LLC now owns 21,007 shares of the medical research company’s stock worth $1,386,000 after buying an additional 452 shares during the last quarter. Finally, CIBC Asset Management Inc lifted its holdings in shares of Edwards Lifesciences by 6.6% during the third quarter. CIBC Asset Management Inc now owns 125,400 shares of the medical research company’s stock worth $8,275,000 after buying an additional 7,749 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $67.76 on Friday. The stock’s fifty day moving average is $67.44 and its 200-day moving average is $76.18. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a market capitalization of $39.96 billion, a PE ratio of 9.78, a PEG ratio of 3.81 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 earnings per share. Equities research analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,133,916.72. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,250 shares of company stock worth $2,744,438. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of a number of research analyst reports. Truist Financial cut their price target on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a report on Friday, October 25th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Canaccord Genuity Group lowered their price objective on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Finally, Oppenheimer restated an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.